Rosetta Genomics (ROSG) - microRNA Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rosetta Genomics (ROSG) - microRNA

ROSG 0.430

0.0%

May 21 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (33)	1/17/2009 5:56:57 PM
From: rkrw	Read Replies (1) of 58

The trouble with the test is the data hasn't been very good. Someone could have non cancerous or pre cancerous polyps I assume, best removed, but wouldn't show up in a diagnostic. Just thinking out loud. I think sqnm has an obsession with buying out anyone who hints of prenatal diagnostic patents. They acquired urine i.p. with absolutely no evidence it works from a nearly bankrupt biotech a few months back. I would guess digital and reproductive caught sqnm's eye? From exas quarterly report in November For example, we have intellectual property broadly directed to the detection of allelic and chromosomal imbalances regardless of platform, as well as more platform-specific IP relating to primer extension, Digital PCR, and BEAMing techniques, which we believe are also applicable in the field of reproductive health.” Perhaps if rosetta wants an exit they can make noise about mirna's for fetal dx. :)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next